Standardization of cardiac markers.

Area of Science:

• Clinical Biochemistry
• Cardiovascular Diagnostics
• Immunoassay Standardization

Background:

• Accurate measurement of cardiac biomarkers is essential for diagnosing and managing cardiovascular conditions.
• Variability in immunoassay performance impacts clinical decision-making for cardiac risk assessment.
• The International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Committee on Standardization of Markers of Cardiac Damage (C-SMCD) addresses these issues.

Purpose of the Study:

• To review the current status of standardization for key cardiac biomarkers.
• To discuss quality specifications for immunoassays used in clinical practice.
• To ensure consistent worldwide utilization of cardiac biomarker assays.

Main Methods:

• Literature review of standardization efforts for myoglobin, creatine kinase MB, cardiac troponin I, and natriuretic peptides (BNP, NT-proBNP).
• Analysis of existing quality specifications for analytical immunoassays.
• Evaluation of progress made by the IFCC C-SMCD.

Main Results:

• Identified ongoing standardization challenges for cardiac troponin I and natriuretic peptides.
• Highlighted the need for robust quality specifications to ensure assay reliability.
• Demonstrated the importance of reference materials for assay calibration.

Conclusions:

• Standardization of cardiac biomarkers is critical for reliable diagnostics and risk assessment.
• Implementing quality specifications will improve the consistency and clinical utility of immunoassays.
• Continued efforts are needed for the global harmonization of cardiac biomarker testing.